Truth Frequency Radio

Feb 02, 2013

A new chemo drug – and a new hope


Staring Down Cancer

Published January 17, 2013

Happy New Year! I took someone’s advice and decided to rest, rest, rest over the holidays.

That lasted for a day. I’d like to meet the mom who can actually rest over the holidays. So I did the second best thing: I rested after the holidays. I tried to be patient while I waited to hear if I had been accepted into a new phase one clinical trial.

The seven chemotherapy drugs I have taken over the last year and a half were a bust. My doctor hates to hear me say that, because he feels that even if they stopped working after three months, there was still some level of success involved. That’s a hard concept to grasp when there are a limited number of chemotherapy drugs available. When there aren’t any more, there aren’t any more. I guess you could say it’s the same as looking at a glass being half empty or half full. After being in treatment for so long and knowing that the tumors are in a vital organ, my liver, it’s not easy to stay positive. I do the best I can.

But this brings me to share with you some great news. I have been accepted into a phase one clinical trial for estrogen-positive breast cancer. This drug is being touted as the biggest breakthrough in breast cancer since Dr. Dennis Slamon identified the HER2/neu oncogene and the resulting treatment drug Herceptin.

At this stage, the drug involved in the trial is referred to only as “LY2835219.” I had my first day in the clinical trial yesterday. I spent eleven hours at the hospital with blood draws every two hours, received four electrocardiograms, a skin biopsy, a liver biopsy the day before, etc.

I am really excited and hopeful. I am one of 100 women participating in this study nationwide. They believe that this will be the first oral chemotherapy that will not have any side effects.

Since its inception, this is what The Noreen Fraser Foundation has been working on – devoting research funds to find a treatment, which will allow us to have our lives back. A chemo that will have few or no side effects, enabling us to live normal lives with cancer and not die from it. Basically, a drug that will turn cancer into a chronic disease that can be managed.

Read more

Study accidentally exposes chemotherapy as fraud – tumors grow faster after chemo!

Thursday, January 24, 2013 by: Jonathan Benson, staff writer

chemotherapy(NaturalNews) A team of researchers from Washington state had a giant “Oops!” moment recently when it accidentally uncovered the deadly truth about chemotherapy while investigating why prostate cancer cells are so difficult to eradicate using conventional treatment methods. As it turns out, chemotherapy does not actually treat or cure cancer at all, according to the study’s findings, but rather fuels the growth and spread of cancer cells, making them much harder to stamp out once chemotherapy has already been initiated.

You might call it the “smoking gun” that proves, once and for all, the complete fraud of the conventional cancer industry. Not only is chemotherapy, the standard method of cancer treatment today, a complete flop, based on the findings, but it is actually detrimental for patients with cancer. Published in the journal Nature Medicine, the shock findings which, not surprisingly, are being ignored by the mainstream scientific community, highlight in full detail how chemotherapy causes healthy cells to release a protein that actually feeds cancer cells and causes them to thrive and proliferate.

According to the study, chemotherapy induces healthy cells to release WNT16B, a protein that helps promote cancer cell survival and growth. Chemotherapy also definitively damages the DNA of healthy cells, a long-term detriment that persists long after chemotherapy treatment is stopped. This combined action of healthy cell destruction and cancer cell promotion technically makes chemotherapy more of a cancer-causing protocol than a cancer-treatment protocol, by definition, a fact that should grab the attention of anyone personally familiar with having, or knowing someone else who has cancer.

“WNT16B, when secreted, would interact with nearby tumor cells and cause them to grow, invade, and importantly, resist subsequent therapy,” explained study co-author Peter Nelson from the Fred Hutchinson Cancer Research Centerin Seattle, Washington, about the findings, which he dubbed “completely unexpected.” “Our results indicate that damage responses in benign cells … may directly contribute to enhanced tumor growth kinetics,” added the entire team about what they observed.

Bevacizumab’s Indication Extended in Colorectal Cancer

Zosia Chustecka


Jan 24, 2013

Bevacizumab (Avastin, Genentech/Roche) is already approved for use in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer, but the drug now has an extended indication. The US Food and Drug Administration has approved new labeling, which allows the use of bevacizumab to be continued after disease progression. The European product labeling has also been updated.

“The majority of people diagnosed with metastatic colorectal cancer receive [bevacizumab] plus chemotherapy as their initial treatment,” said Hal Barron, MD, chief medical officer at Genentech, in a press release. “These people now have the option to continue with [bevacizumab] plus a new chemotherapy after their cancer worsens, which may help them live longer than changing to a new chemotherapy alone,” he explained.

The clinical data to support this indication come from the phase 3 ML18147 study, which was presented last year at the annual meeting of the American Society of Clinical Oncology, and reported at the time by Medscape Medical News.

Many oncologists in the United States are already extending bevacizumab beyond first progression; this study gives justification for that, said Bruce J. Roth, MD, professor of medicine in the division of oncology at Washington University School of Medicine in St. Louis, Missouri.

At the meeting last year, Dr. Roth explained that the trial was well designed and demonstrated the benefit of continuation, but didn’t address the magnitude of that benefit. “That’s…for individual physicians and their patients to decide,” he added.

One issue is the high cost of the drug, and the question of “whether it is worth these months of second-line therapy,” Dr. Roth said. “It’s hard to know where that breakpoint is, but this study provides a scientific benefit for that strategy.”

Full Article


Shifting gears in therapy


Staring Down Cancer

Published January 10, 2013

  • Chemotherapy
    © Micah Young

Noreen asked me – the guy in her life – to write her blog this week.

Things are happening fast with the chemo. We have just ended Chemo 7. The tests showed some lowering of the markers, but there is some scaring of the liver – so they have decided to shift gears.

A new chemo in pill form is being developed. It looks like Noreen will be accepted in the study. Nor has been affected by every side-effect known to man. This new developing chemo’s goal is to make breast cancer cells sensitive to estrogen inhibitors. In Noreen’s case, if it works, she could be sensitive again like she was when she was on Femara.

The question now is her liver. She has scarring, and tomorrow she must get a liver biopsy. Naturally she is nervous. We have been told that a liver transplant is out of the question, since the cancer is in her blood stream, and a new liver will be infected immediately.

So we enter another waiting game.

I want to say that my wonderful wife is the strongest person I know. She takes life head-on. We can only pray for a successful test.

Read more